IFP Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

IFP Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-202	Closed	-$7K	–	3502
2021 Q2	$7K	Buy	+202	New	+$6.19K	﹤0.01%	2373

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

IFP Advisors's DRNA Position: Q3 2021 in Review

IFP Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 202 shares — an estimated $7K sold.

IFP Advisors first reported a position in DRNA in Q2 2021 and held it in 1 quarter. The position peaked at $7K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

IFP Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
IFP Advisors sold 202 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $7K.
IFP Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
IFP Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $7K in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on IFP Advisors's 13F filing for Q3 2021, filed 6 Oct 2021.